References
- Cooke T , ReevesJ, LaniganA et al. HER2 as a prognostic and predictive marker for breast cancer. Ann. Oncol. 12(Suppl. 1) , S23–S28 (2001).
- Harvey J , ClarkG, OsborneC et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J. Clin. Oncol. 17(5) , 1474–1481 (1999).
- Kim C , TangG, Pogue-GeileK et al. Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer. J. Clin. Oncol. 29(31) , 4160–4167 (2011).
- Nahta R , O‘ReganR. Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers. Breast Cancer Res. Treat.135(1) , 39–48 (2012).
- Goldhirsch A , WoodW, CoatesA et al. Strategies for subtypes – dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann. Oncol. 22(8) , 1736–1747 (2011).
References
- Carmeliet P , JainRK. Molecular mechanisms and clinical applications of angiogenesis. Nature473 , 298–307 (2011).
- Lambrechts D , LenzHJ, HaasS et al. Markers of response for the antiangiogenic agent bevacizumab. J. Clin. Oncol. 31(9) , 1219–1230 (2013).
- Miles D , ChanA, DirixL et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol. 28(20) , 3239–3247 (2010).
References
- Thomas E , GomezH, LiR et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J. Clin. Oncol. 25(33) , 5210–5217 (2007).
- Fornier M : Epothilones in breast cancer: review of clinical experience.Ann. Oncol.18(Suppl. 5) , 21 (2007).
- Dumontet C , JordanM, LeeF. Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies. Mol. Cancer Ther.8(1) , 17–25 (2009).
- von Minckwitz G , UntchM, Blohmer J-U et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J. Clin. Oncol.30(15) , 1796–1804 (2012).